José is a dual-national French / Swiss expert in deep technology development and commercialisation with a combined academic, institutional and industrial experience.
José graduated from the Ecole Normale Supérieure in Paris with PhDs in Physics and Geophysics and subsequently completed a postdoc at Stanford University. He has served as a Professor at the Institut de Physique du Globe de Paris, one of the campuses of the Université Paris Cité.
While publishing numerous scientific papers, José also published, in 2005, a book essay on the economics of space for environment and security: Les Sentinelles de la Terre.
With an industrial and product development perspective, José has served as Executive Director of several French and international R&D agencies including BRGM, CNES and the European Space Agency. He is currently serving as the Chairman and Director of several deep technology companies in Switzerland, Italy and France and is an entrepreneur at heart.
He was Senior VP "Mergers and Acquisitions and Business Development" in Sanofi and member of the Executive Committee. He participated to the genesis of ILTOO Pharma regarding business matters. Throughout his career in the pharmaceutical industry, he was dedicated to licensing and Merger & Acquisitions activities being an enabler for Sanofi’s growth in the last 20 years. Jean-Michel brings ILTOO Pharma its overall strategic vision and its extensive experience in business development and negotiations.
Jean Michel holds a Master Degree in business administration from Paris HEC Business School.
Pierre is a co-founder and Chief Executive Officer of Enterome. He has been a member of the founding teams of several biotech companies. Before creating Enterome in 2012, Pierre was VP M&A and business development at Sanofi Ophthalmology. Being the founder and COO of Fovea Pharmaceuticals, he has been instrumental in building up the product-portfolio that became the Ophthalmology division of Sanofi (Fovea was acquired by sanofi in 2009, less than five years after inception).
Earlier, Pierre was VP Business Development at UroGene, a company sold to Pierre Fabre in 2004. In 2000, he took over the position of head of European commercial operations at Ethypharm. Prior to this, Pierre held various positions in science and business development at Fournier Pharma. Pierre is PharmD, PhD and holds a MBA from INSEAD.
Dorothée has spent her career in the Bio Pharmaceutical industry. During this time, she served as CEO of the Transgenic Alliance as well as Chief Scientist with Transgene. She now spends her time advising new and growing Bio Pharma companies. Dorothée earned her Bachelor of Science in Engineering at tech Institut Agro-Alimentaire from ENSIA and later earned her MBA from INSEAD. Dorothée was an early investor in ILTOO Pharma and currently serves as an Advisor and member of the Board of Directors.
Professor of Immunology, Head of Biotherapy research unit at UPMC University and medical school and Coordinator of the Investigational Clinical Centre (CIC-BT) in La Pitié-Salpêtrière hospital (Paris, France), David has been devoted to translational research and clinical immunology. His work goes from fundamental immunology to pathophysiology of immune-related disorders. Since these past 20 years, he developed a first-level expertise in the research field of immune tolerance and homeostasis. In particular, he explored the role of regulatory T cells and pioneered the field of immune regulation by performing the first trial ever evaluating low dose IL2 in patients with autoimmune diseases (i.e. vasculitis). David is co-inventor of more than 30 patents and published more than 200 articles in peer-reviewed journals.